Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSTB100 SAD and MAD Study in Healthy Adults
NCT07702279Phase 1Recruiting
- Sponsor
- Prospect Therapeutics
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PSTB100 (2 arms), sponsored by Prospect Therapeutics. Primary endpoints: Time to Reach Maximum Observed Plasma concentration, Maximum Observed Plasma Concentration and 12 more. Started Jul 2026; status: recruiting.
02
Drugs
PSTB100
Beyond the preview
Go deeper on NCT07702279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702279.